PALB2 and familial pancreatic carcinoma: Beyond BRCA and PALB2, additional germline mutations associated with a DNA damage repair deficient phenotype have been identified in patients with pancreatic cancer and may represent novel therapeutic targets and predictors of response to platinum-based therapy and PARP inhibition.21,30,31 The role of these mutations as predictive biomarkers is being actively investigated.